Skip to main content
Press release November 12, 2026

NeuroPace Reports Third Quarter 2026 Financial Results and Provides Revised Full Year Guidance

NeuroPace Inc (NPCE)

--Q3 2026 total revenue of $23.1 million, including $22.9 million in RNS revenue representing 1% growth-- --Revises full year 2026 revenue guidance to $91 million to $92 million; focused on improving commercial execution and accelerating growth-- --Advances innovation pipeline with NeuroPace Remote Care™ FDA submission and upcoming IGE PMA-S Amendment, supporting significant long-term growth opportunities-- MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the third quarter ended September 30, 2026, and provided a corporate update. Third Quarter 2026 Financial Highlights Total revenue of $23.1 million in the third quarter of 2026 RNS System revenue of $22.9 million in the quarter, representing 1.4% growth compared to the third quarter of 2025 Net loss in the third quarter of 2026 was ($3.3) million compared to ($4.9) million in the third quarter of 2025 Adjusted EBITDA of $0.4 million for the third quarter of 2026, compared to ($1.3) million in the third quarter of 2025 Third Quarter 2026 Operational & Strategic Highlights Completed a Submission Issue Request (SIR) meeting with the FDA in October regarding the Company’s premarket approval (PMA) supplement for idiopathic generalized epilepsy (IGE). NeuroPace is incorporating the agency’s feedback into an amendment and expects to submit the amendment around year end. Submitted a PMA-Supplement for Remote Care to the FDA, with a planned 180-day review cycle. Remote Care is designed to enable physicians to program the RNS System through telehealth, reducing the need for in-person visits and helping address travel and geographic barriers that can limit access to RNS therapy, particularly for patients who live farther from epilepsy centers. Initiated enrollment in AURORA, a real-world evidence study designed to support expansion of the RNS System’s indication to adolescents aged 12–17 with drug-resistant focal epilepsy. Data collection is expected to be completed in early 2027, followed by analysis and submission to the FDA. “Third-quarter revenue was below our expectations, and we have taken and are taking action to improve commercial execution and return the business to historical growth rates,” said Joel Becker, President and Chief Executive Officer of NeuroPace. “The shortfall was concentrated in several of our largest accounts and reflected isolated account-level issues and changes to our field organization that created more disruption than anticipated. We are addressing these factors, and fourth-quarter scheduled cases have begun to recover. Ongoing demand for RNS therapy, compelling clinical outcomes and the substantial opportunity within our current indication all remain and reinforce our confidence in the business performing in line with historical growth rates. Our focus is on continuing to translate that opportunity into consistent growth through deeper customer engagement and stronger commercial execution.” “Our innovation pipeline represents one of the most significant opportunities ahead for NeuroPace, combining potential indication expansion with capabilities that can make RNS therapy more accessible, efficient and personalized,” Becker continued. “Following our SIR meeting with the FDA, we are preparing the amendment to our IGE submission. We have also initiated enrollment in AURORA, our real-world evidence study supporting potential expansion into adolescent focal epilepsy, and submitted Remote Care for FDA review. Together with ECoG Assistant, our broader AI development programs and our next-generation platform, these initiatives can extend our reach to new patient populations and strengthen the differentiated value of RNS therapy. We believe the opportunity in our core business and the breadth of our pipeline position NeuroPace for substantial long-term growth.” Third Quarter 2026 Financial Results RNS System revenue totaled $22.9 million in the third quarter of 2026, representing growth of 1.4% compared to the third quarter of 2025. Total revenue in the third quarter of 2026 declined 1.1% to $23.1 million, compared with revenue of $23.4 million in the third quarter of 2025. Non-GAAP gross margin for the third quarter of 2026 was 84.8%, compared with 82.8% in the third quarter of 2025. The slight year-over-year growth was driven by improved labor absorption. Total GAAP gross margin from continuing operations in the third quarter of 2026 was 84.3%. Non-GAAP operating expenses in the third quarter of 2026 were $19.2 million, compared with $20.7 million in the third quarter of 2025. GAAP operating expenses in the third quarter of 2026 were $21.6 million. Non-GAAP sales and marketing expense in the third quarter of 2026 was $10.5 million, compared with $11.2 million in the third quarter of 2025. The year-over-year decline was largely due to a decrease in personnel-related expenses resulting from a decrease in sales and field support personnel costs, including sales commissions, partially offset by an increase in headcount. Non-GAAP research and development expense in the third quarter of 2026 was $5.5 million, compared with $5.8 million in the third quarter of 2025. The year-over-year decline was primarily driven by a decrease in personnel-related expenses, including variable compensation, partially offset by less grant funds received primarily from the National Institutes of Health which are recognized as a reduction in research and development expenses. Non-GAAP general and administrative expense in the third quarter of 2026 was $3.2 million compared with $3.7 million in the third quarter of 2025. The year-over-year decline was largely due to a decrease in personnel-related expenses from variable compensation, partially offset by an increase from headcount increase. Non-GAAP income from operations was $0.4 million in the third quarter of 2026, compared with loss from operations of ($1.4) million in the third quarter of 2025. Non-GAAP net loss was ($0.9) million for the third quarter of 2026 compared with net loss of ($2.3) million in the third quarter of 2025. GAAP net loss in the third quarter of 2026 was ($3.3) million. The Company’s cash, cash equivalents, short-term investments and restricted cash balance as of September 30, 2026 was $49.5 million compared with $51.9 million at the end of the prior quarter. Long-term borrowings totaled $59.2 million as of September 30, 2026. Full Year 2026 Financial Guidance Revise total revenue guidance for full year 2026 to between $91 million and $92 million, representing underlying RNS growth of 10% to 11%. This compares to previously issued guidance of $99.5 million to $101.5 million. This guidance continues to reflect expected service revenue of approximately $1 million. Increase full year non-GAAP gross margin to between 83.0% and 83.5%, an increase compared to 82.0% to 83.0% previously. Revise full year non-GAAP operating expenses to be between $85 million and $86 million, compared to previous guidance of $90 million to $92 million. This revised range continues to exclude approximately $10 million in stock-based compensation, a non-cash expense. Revise Adjusted EBITDA to be between ($8.5) million and ($9.5) million compared to previous guidance between ($7.5) million to ($8.5) million. Non-GAAP Measures To supplement NeuroPace’s condensed financial statements presented in accordance with GAAP, the Company uses non-GAAP measures of certain components of financial performance. These non-GAAP measures include Adjusted EBITDA, non-GAAP gross margin, non-GAAP cost of goods sold, non-GAAP sales and marketing expense, non-GAAP research and development expense, non-GAAP general and administrative expense, non-GAAP operating expenses, non-GAAP income (loss) from operations, and non-GAAP net loss from operations. NeuroPace believes the presentation of its non-GAAP financial measures enhances the user’s overall understanding of the Company’s historical financial performance. The presentation of the Company’s non-GAAP financial measures is not meant to be considered in isolation or as a substitute for the Company’s financial results prepared in accordance with GAAP, and the Company’s non-GAAP measures may be different from non-GAAP measures used by other companies. Discontinued Operations & Basis of Presentation The Company’s DIXI Medical product operations are presented as discontinued operations under ASC 205-20. Unless otherwise noted, the results discussed in this release reflect continuing operations; and prior-period amounts have been reclassified on a comparable basis, with no effect on previously reported net loss, total assets, total liabilities, or total stockholders’ equity. See the accompanying financial statements for the GAAP presentation of continuing and discontinued operations. Webcast and Conference Call Information NeuroPace will host a conference call to discuss the third quarter and full year 2026 financial results after market close on Thursday, November 12, 2026, at 4:30 P.M. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at (click here). Individuals interested in participating in the call via telephone may access the call by dialing + 1 (833) 461-5787 and referencing Conference ID 345 741 415. The webcast will be archived on the Company’s investor relations website at https://investors.neuropace.com/news-and-events/events and will be available for replay for at least 90 days after the event. About NeuroPace, Inc. Based in Mountain View, Calif., NeuroPace is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders. Forward Looking Statements This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. NeuroPace may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements regarding: Expectations regarding the Company’s future revenue and growth based on a continued operations basis, excluding revenue from the DIXI Medical product operations; NeuroPace’s expectations, forecasts and beliefs with respect to potential indication expansion for its RNS System and its software, technology and other product development efforts; increasing access to and adoption of RNS therapy as the standard of care in drug-resistant epilepsy; NeuroPace’s continued execution on its long-term revenue growth strategy, including with respect to sustained revenue growth and long-term value creation. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: actual operating results may differ significantly from any guidance provided; uncertainties related to market acceptance and adoption of NeuroPace’s RNS System and impacts to NeuroPace’s revenue for 2026 and in the future; risks that NeuroPace’s operating expenses could be higher than anticipated and that it could use its cash resources sooner than expected; risks that NeuroPace’s gross margin may be lower than forecast; risks related to the pricing of the RNS System and availability of adequate reimbursement for the procedures to implant the RNS System and for clinicians to provide ongoing care for patients treated with the RNS System; risks related to regulatory compliance and expectations for regulatory approvals to expand the market for NeuroPace’s RNS System, including risks related to the NAUTILUS submission, the forthcoming Submission Issue Request (SIR) Q-Sub process, AURORA, and the Remote Care submission; risks related to product development, including risks related to the development of AI-powered software, including NeuroPace AI® and the next generation device platform; risks related to NeuroPace’s reliance on contractors and other third parties, including single-source suppliers and vendors; and other important factors. These and other risks and uncertainties include those described more fully in the section titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in NeuroPace’s public filings with the U.S. Securities and Exchange Commission (SEC), including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, filed with the SEC on November 12, 2026, as well as any other reports that it may file with the SEC in the future. Forward-looking statements contained in this announcement are based on information available to NeuroPace as of the date hereof. NeuroPace undertakes no obligation to update such information except as required under applicable law. These forward-looking statements should not be relied upon as representing NeuroPace’s views as of any date subsequent to the date of this press release and should not be relied upon as a prediction of future events. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of NeuroPace. NeuroPace, Inc. Condensed Statements of Operations and Comprehensive Loss (unaudited) Three Months Ended September 30, Nine Months Ended September 30, (in thousands, except for share and per share amounts) 2026 2025 2026 2025 Revenue $ 23,104 $ 23,351 $ 67,933 $ 61,173 Cost of goods sold 3,633 4,181 11,545 10,659 Gross profit 19,471 19,170 56,388 50,514 Operating expenses: Sales and marketing 11,169 12,025 34,876 33,919 Research and development 6,166 6,576 20,253 20,861 General and administrative 4,216 4,594 14,087 14,708 Total operating expenses 21,551 23,195 69,216 69,488 Loss from continuing operations (2,080 ) (4,025 ) (12,828 ) (18,974 ) Interest income 511 667 1,599 2,178 Interest expense (1,565 ) (1,645 ) (4,625 ) (5,857 ) Other income (expense), net (164 ) 82 (370 ) (486 ) Net loss and comprehensive loss from continuing operations $ (3,298 ) $ (4,921 ) $ (16,224 ) $ (23,139 ) Net income from discontinued operations $ — $ 1,425 $ 37 $ 4,403 Net loss and comprehensive loss $ (3,298 ) $ (3,496 ) $ (16,187 ) $ (18,736 ) Net loss per share from continuing operations attributable to common stockholders, basic and diluted $ (0.10 ) $ (0.15 ) $ (0.48 ) $ (0.71 ) Net income per share from discontinued operations attributable to common stockholders, basic and diluted $ 0.00 $ 0.04 $ 0.00 $ 0.13 Net loss per share attributable to common stockholders, basic and diluted $ (0.10 ) $ (0.11 ) $ (0.48 ) $ (0.58 ) Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted 34,346,892 33,134,606 34,058,353 32,498,907 NeuroPace, Inc. Condensed Balance Sheets (unaudited) September 30, December 31, (in thousands, except for share and per share amounts) 2026 2025 Assets Current assets: Cash and cash equivalents $ 10,235 $ 21,692 Short-term investments 38,996 39,366 Accounts receivable 14,275 12,936 Inventory 18,800 14,862 Prepaid expenses and other current assets 2,234 1,438 Current assets of discontinued operations — 3,779 Total current assets 84,540 94,073 Property and equipment, net 1,164 1,125 Operating lease right-of-use asset 8,740 10,132 Restricted cash 242 122 Other assets 89 113 Total assets $ 94,775 $ 105,565 Liabilities and Stockholders’ Equity Current liabilities: Accounts payable $ 3,240 $ 1,776 Accrued liabilities 10,383 13,184 Operating lease liability 2,327 2,117 Deferred revenue 120 141 Current liabilities of discontinued operations — 596 Total current liabilities 16,070 17,814 Long-term debt 59,158 58,884 Operating lease liability, net of current portion 8,055 9,836 Total liabilities 83,283 86,534 Stockholders’ equity: Common stock, $0.001 par value 34 34 Additional paid-in capital 580,060 571,412 Accumulated deficit (568,602 ) (552,415 ) Total stockholders’ equity 11,492 19,031 Total liabilities and stockholders’ equity $ 94,775 $ 105,565 NeuroPace, Inc. Condensed Statements of Cash Flows (unaudited) Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2026 2025 2026 2025 Cash flows from operating activities Net loss $ (3,298 ) $ (3,496 ) $ (16,187 ) $ (18,736 ) Adjustments to reconcile net loss to net cash used in operating activities: Stock-based compensation expense 2,430 2,628 7,011 8,482 Depreciation 80 54 206 158 Amortization of debt discount and issuance costs 71 70 209 174 Non-cash interest expense 80 73 237 463 Loss on debt extinguishment — — — 527 Amortization of right-of-use asset 475 433 1,392 1,268 Unrealized loss (gain) on short-term investments 164 (82 ) 370 (41 ) Inventory write-downs 169 47 313 140 Loss on disposal of property and equipment — — — 2 Changes in operating assets and liabilities: Accounts receivable 655 (1,383 ) 406 (2,087 ) Inventory (858 ) (1,836 ) (2,218 ) (4,894 ) Prepaid expenses and other assets (780 ) (537 ) (794 ) 134 Accounts payable (946 ) (48 ) 1,037 1,655 Accrued liabilities (467 ) 2,650 (2,956 ) 2,530 Deferred revenue (3 ) (48 ) (21 ) 93 Operating lease liabilities (535 ) (469 ) (1,571 ) (1,380 ) Net cash used in operating activities (2,763 ) (1,944 ) (12,566 ) (11,512 ) Cash flows from investing activities Acquisition of property and equipment (16 ) (30 ) (258 ) (235 ) Net cash used in investing activities (16 ) (30 ) (258 ) (235 ) Cash flows from financing activities Proceeds from issuance of common stock in follow-on offering, net of underwriting discounts and commissions — (50 ) — 69,654 Repurchase of common stock from KCK Ltd. — — — (49,546 ) Proceeds from issuance of common stock under employee plans 539 1 1,926 1,152 Taxes withheld and paid related to net share settlement of equity awards (62 ) (53 ) (289 ) (455 ) Proceeds from At-the-Market offering, net of sales commission — — — 232 Proceeds from debt, net of discounts and issuance costs — (133 ) — 58,435 Payment of annual debt fee — — (150 ) — Repayment of debt — — — (60,507 ) Net cash provided by (used in) financing activities 477 (235 ) 1,487 18,965 Net increase (decrease) in cash and cash equivalents (2,302 ) (2,209 ) (11,337 ) 7,218 Cash, cash equivalents and restricted cash at the Beginning of the Period 12,779 22,979 21,814 13,552 Cash, cash equivalents and restricted cash at the End of the Period $ 10,477 $ 20,770 $ 10,477 $ 20,770 Reconciliation of cash, cash equivalents and restricted cash to balance sheets: Cash and cash equivalents $ 10,235 $ 20,648 $ 10,235 $ 20,648 Restricted cash 242 122 242 122 Cash, cash equivalents and restricted cash in balance sheets $ 10,477 $ 20,770 $ 10,477 $ 20,770 NeuroPace, Inc. Table 1. 2025 GAAP to Non-GAAP Reconciliations from Continuing Operations (unaudited) Three Months Ended Year Ended (in thousands) March 31, 2025 June 30, 2025 September 30, 2025 December 31, 2025 December 31, 2025 RNS revenue $ 18,151 $ 18,564 $ 22,580 $ 22,374 $ 81,669 Service revenue 170 937 771 886 2,764 Revenue $ 18,321 $ 19,501 $ 23,351 $ 23,260 $ 84,433 GAAP cost of goods sold $ 3,190 $ 3,288 $ 4,181 $ 4,405 $ 15,064 Stock-based compensation 178 173 168 175 694 Non-GAAP cost of goods sold $ 3,012 $ 3,115 $ 4,013 $ 4,230 $ 14,370 GAAP sales and marketing expense $ 10,405 $ 11,489 $ 12,025 $ 10,713 $ 44,632 Stock-based compensation 783 761 781 727 3,052 Non-GAAP sales and marketing expense $ 9,622 $ 10,728 $ 11,244 $ 9,986 $ 41,580 GAAP research and development expense $ 7,440 $ 6,845 $ 6,576 $ 7,027 $ 27,888 Stock-based compensation 872 865 821 848 3,406 Non-GAAP research and development expense $ 6,568 $ 5,980 $ 5,755 $ 6,179 $ 24,482 GAAP general and administrative expense $ 4,046 $ 6,068 $ 4,594 $ 4,382 $ 19,090 Stock-based compensation 793 1,429 858 857 3,937 Non-GAAP general and administrative expense $ 3,253 $ 4,639 $ 3,736 $ 3,525 $ 15,153 GAAP operating expenses $ 21,891 $ 24,402 $ 23,195 $ 22,122 $ 91,610 Stock-based compensation 2,448 3,055 2,460 2,432 10,395 Non-GAAP operating expenses $ 19,443 $ 21,347 $ 20,735 $ 19,690 $ 81,215 GAAP loss from continuing operations $ (6,760 ) $ (8,189 ) $ (4,025 ) $ (3,267 ) $ (22,241 ) Stock-based compensation 2,626 3,228 2,628 2,607 11,089 Non-GAAP loss from continuing operations $ (4,134 ) $ (4,961 ) $ (1,397 ) $ (660 ) $ (11,152 ) Depreciation 49 55 54 80 238 Adjusted EBITDA from continuing operations (Non-GAAP) $ (4,085 ) $ (4,906 ) $ (1,343 ) $ (580 ) $ (10,914 ) GAAP loss from continuing operations $ (6,760 ) $ (8,189 ) $ (4,025 ) $ (3,267 ) $ (22,241 ) Interest and other income (expense), net (1,442 ) (1,827 ) (896 ) (962 ) (5,127 ) GAAP net loss from continuing operations $ (8,202 ) $ (10,016 ) $ (4,921 ) $ (4,229 ) $ (27,368 ) Stock-based compensation 2,626 3,228 2,628 2,607 11,089 Non-GAAP net loss from continuing operations $ (5,576 ) $ (6,788 ) $ (2,293 ) $ (1,622 ) $ (16,279 ) NeuroPace, Inc. Table 2. 2026 GAAP to Non-GAAP Reconciliations from Continuing Operations (unaudited) Three Months Ended Nine Months Ended (in thousands) March 31, 2026 June 30, 2026 September 30, 2026 September 30, 2026 RNS revenue $ 21,689 $ 22,524 $ 22,901 $ 67,114 Service revenue 314 302 203 819 Revenue $ 22,003 $ 22,826 $ 23,104 $ 67,933 GAAP cost of goods sold $ 3,992 $ 3,920 $ 3,633 $ 11,545 Stock-based compensation 138 126 118 382 Non-GAAP cost of goods sold $ 3,854 $ 3,794 $ 3,515 $ 11,163 GAAP sales and marketing expense $ 11,583 $ 12,124 $ 11,169 $ 34,876 Stock-based compensation 595 650 656 1,901 Non-GAAP sales and marketing expense $ 10,988 $ 11,474 $ 10,513 $ 32,975 GAAP research and development expense $ 7,189 $ 6,898 $ 6,166 $ 20,253 Stock-based compensation 713 624 647 1,984 Non-GAAP research and development expense $ 6,476 $ 6,274 $ 5,519 $ 18,269 GAAP general and administrative expense $ 4,844 $ 5,027 $ 4,216 $ 14,087 Stock-based compensation 832 903 1,009 2,744 Non-GAAP general and administrative expense $ 4,012 $ 4,124 $ 3,207 $ 11,343 GAAP operating expenses $ 23,616 $ 24,049 $ 21,551 $ 69,216 Stock-based compensation 2,140 2,177 2,312 6,629 Non-GAAP operating expenses $ 21,476 $ 21,872 $ 19,239 $ 62,587 GAAP loss from continuing operations $ (5,605 ) $ (5,143 ) $ (2,080 ) $ (12,828 ) Stock-based compensation 2,278 2,303 2,430 7,011 Non-GAAP income (loss) from continuing operations $ (3,327 ) $ (2,840 ) $ 350 $ (5,817 ) Depreciation 60 66 80 206 Adjusted EBITDA from continuing operations (Non-GAAP) $ (3,267 ) $ (2,774 ) $ 430 $ (5,611 ) GAAP loss from continuing operations $ (5,605 ) $ (5,143 ) $ (2,080 ) $ (12,828 ) Interest and other income (expense), net (1,121 ) (1,057 ) (1,218 ) (3,396 ) GAAP net loss from continuing operations $ (6,726 ) $ (6,200 ) $ (3,298 ) $ (16,224 ) Stock-based compensation 2,278 2,303 2,430 7,011 Non-GAAP net loss from continuing operations $ (4,448 ) $ (3,897 ) $ (868 ) $ (9,213 ) NeuroPace, Inc. Table 3. GAAP to Non-GAAP Reconciliations 2026 Revised Guidance (in thousands) 2026 Guidance RNS revenue $90,000 to $91,000 Service revenue ~1,000 Revenue $91,000 to $92,000 GAAP gross margin 83.0% Stock-based compensation ~50 bps Non-GAAP gross margin 83.0% to 83.5% GAAP sales and marketing expense ~$48,000 to $49,000 Stock-based compensation ~3,000 Non-GAAP sales and marketing expense $45,000 to $46,000 GAAP research and development expense ~$28,000 Stock-based compensation ~3,000 Non-GAAP research and development expense ~$25,000 GAAP general and administrative expense ~$19,000 Stock-based compensation ~4,000 Non-GAAP general and administrative expense ~$15,000 GAAP operating expenses $95,000 to $96,000 Stock-based compensation ~10,000 Non-GAAP operating expenses $85,000 to $86,000 GAAP loss from operations ($19,250) to ($20,250) Stock-based compensation (including gross margin) ~10,500 Non-GAAP loss from operations (8,750) to (9,750) Depreciation ~250 Adjusted EBITDA (Non-GAAP) ($8,500) to ($9,500) Investor Contact: Scott Schaper Vice President, Finance and Investor Relations sschaper@neuropace.com investors@neuropace.com Source: NeuroPace, Inc.
View original release